Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.

Two vortioxetine doses were investigated because both 10 mg and 20 mg demonstrated nominally significant improvements in MADRS total score and response rate, and acceptable tolerability, in the secondary analysis of a randomized, placebo-controlled, multinational, 8-week, phase 2/3 trial of vortioxetine that included Japanese participants with MDD. 24 After the treatment period, study drugs were subsequently withdrawn, at which point patients entered a 4-week safety follow-up period for the analysis of outcomes of adverse events.

also in 7,732 other papers